What alternative therapy can be used instead of Breo (fluticasone furoate/vilanterol)?

Alternative Therapies to Breo (Fluticasone Furoate/Vilanterol)

The best alternative to Breo depends on disease severity and whether you're treating asthma or COPD, but for most patients with moderate-to-severe asthma requiring step 3-4 therapy, other ICS/LABA combinations like fluticasone propionate/salmeterol (Advair) or budesonide/formoterol are preferred alternatives, while for COPD, alternative dual bronchodilator combinations or other ICS/LABA formulations are appropriate.

For Asthma Patients

Step 3-4 Therapy Alternatives (Moderate-to-Severe Persistent Asthma)

Preferred ICS/LABA Combinations:

• Fluticasone propionate/salmeterol (Advair) is the most established alternative, administered twice daily, with extensive evidence showing comparable efficacy to Breo in lung function improvement 1.
• Budesonide/formoterol (Symbicort) offers the advantage of both maintenance and reliever therapy (SMART regimen), which may provide superior control in patients with airway inflammation and frequent symptoms 2.

Alternative Add-On Therapies to ICS:

• Medium-dose ICS alone can be considered as an alternative to low-dose ICS/LABA combination at step 3 3.
• Low-dose ICS plus leukotriene receptor antagonist (montelukast or zafirlukast) is an alternative option, though less preferred than ICS/LABA combinations 3.
• Low-dose ICS plus theophylline is another alternative, though requires serum concentration monitoring 3.

Step 2 Therapy Alternatives (Mild Persistent Asthma)

If stepping down or treating milder disease:

• Low-dose ICS monotherapy is the preferred treatment 3.
• Leukotriene receptor antagonists (montelukast once daily or zafirlukast twice daily) are appropriate alternatives for patients unable or unwilling to use ICS, with advantages of ease of use and high compliance rates 3.
• Cromolyn, nedocromil, or theophylline are additional alternatives, though not preferred 3.

Step 5-6 Therapy (Severe Persistent Asthma)

For patients requiring higher-intensity therapy:

• High-dose ICS/LABA combinations remain the foundation 3.
• Omalizumab (Xolair) should be considered as adjunctive therapy for patients ≥12 years with allergic asthma and elevated IgE levels 3.
• Oral systemic corticosteroids may be added at step 6 for severe persistent asthma 3.

For COPD Patients

Alternative ICS/LABA Combinations

• Fluticasone propionate/salmeterol 250/50 mcg twice daily provides similar lung function improvements to Breo, with comparable safety profiles 4.
• Budesonide/glycopyrrolate/formoterol (BUD/GLY/FORM) is a single-inhaler triple therapy option, though recent evidence suggests Breo (as part of FF/UMEC/VI triple therapy) may provide better exacerbation control 5.

LABA/LAMA Combinations (Without ICS)

For patients who don't require ICS or cannot tolerate it:

• Vilanterol/umeclidinium offers once-daily dual bronchodilation without corticosteroid 3.
• Tiotropium/olodaterol is another once-daily LABA/LAMA combination 3.
• Aclidinium/formoterol, glycopyrronium/indacaterol, or glycopyrronium/formoterol are additional LABA/LAMA options under development or available 3.

Monotherapy Options

• Long-acting muscarinic antagonists (LAMAs) such as tiotropium, umeclidinium, or glycopyrronium can be used as monotherapy 3.
• Long-acting beta-agonists (LABAs) like olodaterol or vilanterol as monotherapy, though LAMA is generally preferred 3.

Key Clinical Considerations

Safety Caveat for LABAs:

• LABAs should never be used as monotherapy for asthma long-term control; they must always be combined with ICS 3.
• There are concerns about increased severe exacerbations and deaths when LABAs are added to usual asthma therapy without adequate ICS 3.

ICS Use Criteria for COPD:

• ICS-containing regimens are recommended for COPD patients with FEV1 <50-60% predicted AND ≥2 exacerbations per year, or those with asthma-COPD overlap syndrome 3.
• Be aware of increased pneumonia risk with ICS use in COPD 3.

Adherence Considerations:

• Once-daily regimens like Breo may improve adherence compared to twice-daily alternatives 6, 7.
• However, if switching from Breo, twice-daily alternatives like fluticasone propionate/salmeterol have demonstrated similar clinical outcomes with established safety profiles 4, 1.

Device Considerations:

• Pressurized metered-dose inhalers (pMDIs) offer alternatives for patients with low inspiratory flow who cannot effectively use dry powder inhalers 6.